TPI Composites files for Chapter 11 bankruptcy, plans delisting from Nasdaq
Investing.com - iSpecimen reported on Tuesday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
iSpecimen announced earnings per share of $-0.350 on revenue of $2.58M. Analysts polled by Investing.com EPS of $-0.290 on revenue of $2.86M.
iSpecimen 's are down 35% and is trading at $1.560 , still down 94.62% from its 52 week high of $28.98 set on Monday, November 29, 2021.
iSpecimen shares lost 3.70% to trade at $1.560 in intra-day trade the report.
iSpecimen follows other major Healthcare sector earnings this month
iSpecimen's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar